{"id":"shr2554-analog-tablets-chidamide","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"5-20%","effect":"Vomiting"},{"rate":"5-20%","effect":"Anemia"},{"rate":"5-20%","effect":"Thrombocytopenia"},{"rate":"5-20%","effect":"Neutropenia"},{"rate":"5-20%","effect":"Leukopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This results in the inhibition of cell proliferation and the induction of apoptosis in cancer cells. Chidamide also has immunomodulatory effects, enhancing the activity of immune cells and promoting an anti-tumor immune response.","oneSentence":"Chidamide is a histone deacetylase inhibitor that works by blocking the activity of histone deacetylases, leading to the accumulation of acetylated histones and the activation of tumor suppressor genes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:34:34.215Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory peripheral T-cell lymphoma"},{"name":"Relapsed or refractory cutaneous T-cell lymphoma"}]},"trialDetails":[{"nctId":"NCT06122389","phase":"PHASE3","title":"SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-02-05","conditions":"Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy","enrollment":130}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SHR2554 analog tablets; Chidamide","genericName":"SHR2554 analog tablets; Chidamide","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Chidamide is a histone deacetylase inhibitor that works by blocking the activity of histone deacetylases, leading to the accumulation of acetylated histones and the activation of tumor suppressor genes. Used for Relapsed or refractory peripheral T-cell lymphoma, Relapsed or refractory cutaneous T-cell lymphoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}